期刊文献+

齐拉西酮与利培酮对精神分裂症阴性症状及认知功能的影响 被引量:4

Controlled study of ziprasidone and risperidone effect in negative symptom and cognitive impairment in schizophrenia
下载PDF
导出
摘要 目的探讨齐拉西酮、利培酮对精神分裂症阴性症状和认知功能的影响。方法选取2013年1—9月佛山市顺德区伍仲佩纪念医院住院部所收治的75例精神分裂症患者为研究对象,随机分为齐拉西酮组(n=39)和利培酮组(n=36),分别给予齐拉西酮和利培酮治疗8周。采用精神病阴性与阳性症状量表(PANSS)、韦氏记忆量表(WMS)、威斯康星卡片分类测验(WCST)分别于治疗前及治疗8周后对两组进行评定。结果治疗8周后,齐拉西酮组与利培酮组总体疗效无显著差异(P>0.05),齐拉西酮组精神病阴性症状量表、韦氏记忆测验、威斯康星卡分类测验多项成绩优于治疗前和利培酮组(P<0.05)。结论齐拉西酮比利培酮更有助于阴性症状和认知功能的改善。 Objective To explore the efficacy of ziprasidone and risperidone for improving negative symptom and cognitive function in schizophrenia. Methods In this study,we enrolled 75 schizophrenia patients in our hospital from January 2013 to September 2013. These patients were divided into ziprasidone group( n = 39)and risperidone group( n = 36). Positive and Negative Symptom Scale( PANSS),Wechsler Memory Scale( WMS),Wisconsin Card Sorting Test( WCST) were employed to assess negative symptom and cognitive function before and after treatment respectively for 8 weeks. Results After treatment for 8 weeks,there were no significant differences on overall effect between the two groups( P〈0. 05) and all the results of PANSS,WMS and WCST in ziprasidone group were significantly better than before treatment and risperidone group( P〈0. 05).Conclusions Compared with risperidone, ziprasidone can remarkable improve the negative symptom and cognitive function in patients with schizophrenia.
作者 徐健 黄嘉艺
出处 《齐齐哈尔医学院学报》 2015年第26期3931-3933,共3页 Journal of Qiqihar Medical University
关键词 齐拉西酮 利培酮 精神分裂症 阴性症状 认知功能 Ziprasidone Risperidone Schizophrenia Negative symptoms Cognitive function
  • 相关文献

参考文献10

二级参考文献38

  • 1Meehan K,Zhang F,David S,el al.Breier A:A double-blind,randomized comparison of the efficacy and safety of intramuseular injections of olanzapine,lorazepam,Or placebo in treating acutely agitated patients diagnosed with bipolar mania[J].J Clin Psychopharmacol,2001,21(4):389-397.
  • 2Pappadopulos E,Jensen PS,Schur SB,et al."Real Worid"atypical antipsychotic prescribing practices in public child and adolescent inpatient setting[J].Sehizophr Bull,2002,28(1):111-121.
  • 3Daniel DG,zimbrof DL,potkin SG,et al.Zip 80 ms/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder:a 6-week placebo-controlled trial Ziprasidone Study Group[J].Neuropsyehopharmacology,1999,20(5):491-505.
  • 4Capuano B, Crosby IT, Lloyd EJ. Schizophrenia: genesis, receptorology and current herapeutics[ J ]. Curr Med Chem, 2002,9(5) : 521 - 548.
  • 5Schmidt AW, Lebel LA, Howard HR Jr, et al. Ziprasidone: a novel antipsychotic agent with aunique human receptor binding profile[ J ]. Eur J Pharmacol, 2001,425 (3) : 197 - 201.
  • 6Miceli JJ, Wilner KD, Hansen RA, et al. Single- and multipledose pharrnacokinetics of 2iprasidone under non-fasting conditions in healthy male volunteers [ J ]. Br J Clin Pharmacol, 2000,49(Suppl 1) :S5 - S13.
  • 7Miceli JJ,Hunt T,Cole MJ, et al. The pharmacokinetics of CP-88,059 in healthy male volunteers following oral and intravenous administration(abstract) [ J ]. Clin Pharmacol Ther, 1994,62 :142.
  • 8Prakash C,Kamel A,Gummerus J, et al. Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans[J].Drug Metab Dispos, 1997,25(7) :863 - 872.
  • 9Wilner KD, Tensfeldt TG, Baris B, et al. Single- and multipledose pharmacokinetics of ziprasidone in healthy young and elderly volunteers[J]. Br J Clin Pharmacol,2000,49(Suppl 1 ) : S15 -S20.
  • 10Aweeka F, Jayesekara D, Horton M, et al. The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function[J]. Br J Clin Pharmacol,2000,49(Suppl 1) :S27 - S33.

共引文献128

同被引文献29

引证文献4

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部